Novartis Pharma President: Diovan Mess Hurt Japan Sales And Reputation
This article was originally published in PharmAsia News
Executive Summary
Sales at Novartis in Japan have declined as a result of data falsification allegations for Diovan (valsartan) clinical trials, according to statements made by Pharma Division President David Epstein during an Oct. 3 press conference.